Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob Mice

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Neuroendocrinology

• Publication date

  2000-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1159/000054522PMID 10644901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice

  2004cited by this paper
• Intracerebroventricular Administration of Bromocriptine Ameliorates the Insulin-Resistant/Glucose-Intolerant State in Hamsters

  1999cited by this paper
• Leptin Effects on the Expression of Type‐2 CRH Receptor mRNA in the Ventromedial Hypothalamus in the Rat

  1999cited by this paper
• Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters.

  1999cited by this paper
• Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus

  1999cited by this paper
• Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice.

  1999cited by this paper
• Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists

  1999cited by this paper
• Effects of leptin on corticotropin-releasing factor (CRF) synthesis and CRF neuron activation in the paraventricular hypothalamic nucleus of obese (ob/ob) mice.

  1998cited by this paper
• Central administration of Y5 receptor antisense decreases spontaneous food intake and attenuates feeding in response to exogenous neuropeptide Y.

  1998cited by this paper
• Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse

  1998cited by this paper
• The Dorsomedial Hypothalamic Nucleus Revisited: 1998 Update

  1998cited by this paper
• Role of neuropeptide Y in diet-, chemical- and genetic-induced obesity of mice

  1998cited by this paper
• Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia

  1997cited by this paper
• Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance

  1997cited by this paper
• Inhibition of Food Intake by Neuropeptide Y Y5 Receptor Antisense Oligodeoxynucleotides

  1997cited by this paper
• Functional activation of CRH neurons and expression of the genes encoding CRH and its receptors in food-deprived lean (Fa/?) and obese (fa/fa) Zucker rats.

  1997cited by this paper
• Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice.

  1997cited by this paper
• Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like immunoreactivity in the rat hypothalamus.

  1996cited by this paper
• Dexamethasone rapidly increases hypothalamic neuropeptide Y secretion in adrenalectomized ob/ob mice.

  1996cited by this paper
• Circadian rhythms regulate the- expression of the thrifty genotypelphenotype

  1996cited by this paper
• Neuropeptide Y phase shifts the circadian clock in vitro via a Y2 receptor.

  1996cited by this paper
• Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system.

  1996cited by this paper
• Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal.

  1996cited by this paper
• Specificity of Leptin Action on Elevated Blood Glucose Levels and Hypothalamic Neuropeptide Y Gene Expression in ob/ob Mice

  1996cited by this paper
• Attenuation of the Obesity Syndrome of ob/ob Mice by the Loss of Neuropeptide Y

  1996cited by this paper
• Bromocriptine (Ergoset) Reduces Body Weight and Improves Glucose Tolerance in Obese Subjects

  1996cited by this paper
• Intracerebroventricular neuropeptide Y produces hyperinsulinemia in the presence and absence of food.

  1996cited by this paper
• Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain.

  1995cited by this paper
• A neuroendocrine reappraisal of the dual-centre hypothesis: its implications for obesity and insulin resistance.

  1995cited by this paper
• Cellular colocalization of Fos and neuropeptide Y in the intergeniculate leaflet after nonphotic phase-shifting events.

  1995cited by this paper
• Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks.

  1995cited by this paper
• The role of neuropeptide Y in the antiobesity action of the obese gene product

  1995cited by this paper
• Hypothalamic neuropeptide Y and its gene expression: relation to light/dark cycle and circulating corticosterone.

  1994cited by this paper
• Central nervous system and peripheral abnormalities: clues to the understanding of obesity and NIDDM

  1994cited by this paper
• Adrenal Steroid Receptors: Interactions with Brain Neuropeptide Systems in Relation to Nutrient Intake and Metabolism

  1994cited by this paper
• Role of hypothalamic neuropeptide Y gene expression in body weight regulation.

  1994cited by this paper
• The perifornical area: the major focus of (a) patchily distributed hypothalamic neuropeptide Y-sensitive feeding system(s).

  1993cited by this paper
• Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity.

  1993cited by this paper
• Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters.

  1993cited by this paper
• Differential regulation of neuropeptide Y systems in limbic structures of the rat.

  1993cited by this paper
• Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse.

  1993cited by this paper
• Early modification of neuropeptide Y but not of neurotensin in the suprachiasmatic nucleus of the obese Zucker rat.

  1992cited by this paper
• Glucocorticoids in the CNS regulate BAT metabolism and plasma insulin in ob/ob mice.

  1992cited by this paper
• Beneficial Effect of Intravenous Bolus of Corticotropin-Releasing Factor on Glucose Intolerance of Genetically Obese (fa/fa) Rats

  1992cited by this paper
• The effect of dexamethasone on neuropeptide Y concentrations in specific hypothalamic regions.

  1992cited by this paper
• Central Regulation of Energy Metabolism with Special Reference to Circadian Rhythm

  1992cited by this paper
• Hypothalamic-pituitary-adrenal axis function in the Zucker obese rat.

  1992cited by this paper
• Postnatal development of gonadotropin-releasing hormone and cyclophilin gene expression in the female and male rat brain.

  1991cited by this paper
• Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism.

  1991cited by this paper
• Glucocorticoid and mineralocorticoid receptor-binding characteristics in obese (ob/ob) mice.

  1991cited by this paper
• Effect of reserpine and colchicine on neuropeptide mRNA levels in the rat hypothalamic paraventricular nucleus.

  1991cited by this paper
• Changes in the hypothalamo-pituitary-adrenal axis of genetically obese fa/fa rats: a structural, immunocytochemical, and morphometrical study.

  1990cited by this paper
• A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections.

  1989cited by this paper
• Central corticotropin-releasing factor administration prevents the excessive body weight gain of genetically obese (fa/fa) rats.

  1989cited by this paper
• Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment.

  1989cited by this paper
• Immunohistochemical identification of corticotropin releasing factor-containing neurons projecting to the stalk-median eminence of the rat

  1988cited by this paper
• Intrahypothalamic microinfusion of corticotropin-releasing factor elevates blood glucose and free fatty acids in rats.

  1988cited by this paper
• Adrenalectomy and Steroid Treatment in Obese (ob/ob) and Diabetic (db/db) Mice

  1987cited by this paper
• The corticotropin-releasing factor release in rat hypophysial portal blood is mediated by brain catecholamines.

  1987cited by this paper
• Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection.

  1987cited by this paper
• Neuropeptide Y administration acutely increases hypothalamic corticotropin-releasing factor immunoreactivity: lack of effect in other rat brain regions.

  1987cited by this paper
• Lesions of the Thalamic Intergeniculate Leaflet Alter Hamster Circadian Rhythms

  1986cited by this paper
• Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity.

  1986cited by this paper
• Corticotropin releasing factor: central nervous system sites of action.

  1986cited by this paper
• Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior.

  1985cited by this paper
• The effects of centrally administered neuropeptides on the development of gastric lesions in the rat.

  1985cited by this paper
• An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat.

  1985cited by this paper
• Corticotropin-releasing factor: a physiologic regulator of adrenal epinephrine secretion.

  1985cited by this paper
• Neuropeptide Y immunoreactivity in the hamster geniculo-suprachiasmatic tract.

  1985cited by this paper
• Avian pancreatic polypeptide phase shifts hamster circadian rhythms when microinjected into the suprachiasmatic region.

  1984cited by this paper
• Adrenalectomy reverses insulin resistance in muscle from obese (ob/ob) mice.

  1984cited by this paper
• Neuropeptide Y: a potent inducer of consummatory behavior in rats.

  1984cited by this paper
• Hypothalamic hyperinsulinemia and obesity: role of adrenal glucocorticoids.

  1983cited by this paper
• Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob).

  1983cited by this paper
• Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus.

  1983cited by this paper
• Diminished sympathetic nervous system activity in genetically obese (ob/ob) mouse.

  1983cited by this paper
• Diurnal rhythm for corticosterone in obese (ob/ob) diabetes (db/db) and gold-thioglucose-induced obesity in mice.

  1983cited by this paper
• Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism.

  1982cited by this paper
• Ventral lateral geniculate nucleus efferents to the rat suprachiasmatic nucleus exhibit avian pancreatic polypeptide‐like immunoreactivity

  1982cited by this paper
• The pituitary-adrenal system of the genetically obese (ob/ob) mouse.

  1975cited by this paper

• Dopamine agonists and weight changes in prolactinoma patients

  2025cites this paper
• Personalized approach to prediction and prevention of haloperidol-induced metabolic syndrome

  2025cites this paper
• Exploring the Genetic Contribution in Obesity: an overview of dopaminergic system genes.

  2024cites this paper
• Effects of Prolactin Inhibition on Lipid Metabolism in Goats

  2024cites this paper
• Increasing cumulative cabergoline dose in patients with prolactinoma improves metabolic parameters independently of decrease in prolactin levels

  2024cites this paper
• A Comprehensive Review of Fear of Eating Behaviour in Individuals with Diabetes: Exploring Therapeutic Interventions for Diabulimia.

  2024cites this paper
• A Century of Prolactin: Emerging Perspectives as a Metabolic Regulator

  2024cites this paper
• The interplay between prolactin and cardiovascular disease

  2023cites this paper
• Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects

  2023cites this paper
• Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions

  2023cites this paper
• Metabolic effects of prolactin

  2022cites this paper
• The role of the nucleus accumbens and ventral pallidum in feeding and obesity.

  2021cites this paper
• Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats

  2021cites this paper
• Dopaminergic Control of the Feeding Circuit

  2021influential citation
• Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study

  2021cites this paper
• Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment

  2021cites this paper
• Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet

  2021cites this paper
• Neuropeptide Y interaction with dopaminergic and serotonergic pathways: interlinked neurocircuits modulating hedonic eating behaviours.

  2021cites this paper
• KD-64—A new selective A2A adenosine receptor antagonist has anti-inflammatory activity but contrary to the non-selective antagonist—Caffeine does not reduce diet-induced obesity in mice

  2020cites this paper
• Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma

  2020cites this paper
• The role of spinally located dopamine D2 receptors in the regulation of the blood glucose level in mice

  2020cites this paper
• Dopaminergic Neuron Lesion at the Area of the Biological Clock Pacemaker, Suprachiasmatic Nuclei (SCN) Induces Metabolic Syndrome in Rats

  2020cites this paper
• Circadian‐timed dopamine agonist treatment reverses high‐fat diet‐induced diabetogenic shift in ventromedial hypothalamic glucose sensing

  2020cites this paper
• Ameliorative effect of selegiline in high fat diet induced obesity rat model: Possible role of dopaminergic pathway

  2020cites this paper
• Methylphenidate in children with monogenic obesity due to LEPR or MC4R deficiency improves feeling of satiety and reduces BMI‐SDS—A case series

  2020cites this paper
• Bromocriptine Mesylate Improves Glucose Tolerance and Disposal in a High-Fat-Fed Canine Model.

  2020cites this paper
• Distribution of D1 and D2 receptor- immunoreactive neurons in the paraventricular nucleus of the hypothalamus in the rat.

  2019cites this paper
• Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas

  2019cites this paper
• Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

  2019cites this paper
• Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high‐fat diet

  2018cites this paper
• Modulation of the Plasma Ghrelin Level by Intraventromedial Hypothalamic Microinjection of D2 Receptors Agonist and Antagonist

  2018cites this paper
• The effects of hyperprolactinemia and its control on metabolic diseases

  2018cites this paper
• Role of paraventricular hypothalamic dopaminergic D1 receptors in food intake regulation of food‐deprived rats

  2018cites this paper
• Co-Administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM

  2017cites this paper
• Western diet and its effect on motivation, learning and memory

  2017cites this paper
• Metabolic and Cardiovascular Benefits and Risks of EMD386088—A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor

  2017cites this paper
• BENEFICIAL EFFECT OF BROMOCRIPTINE ON HIGH FAT DIET-INDUCED BODY WEIGHT GAIN, ADIPOSITY AND BIOCHEMICAL ANOMALIES IN WISTAR RATS

  2017cites this paper
• Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin

  2017cites this paper
• Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary

  2016cites this paper
• Effects of cabergoline on blood glucose levels in type 2 diabetic patients

  2016cites this paper
• Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus

  2016cites this paper
• Dopamine agonist effects on hyperglycemia and the cardiometabolic profile

  2016cites this paper
• Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin

  2016cites this paper
• Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases

  2015cites this paper
• Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue

  2015cites this paper
• Role of Fat Soluble Vitamins in the Development of Neural Pathways Regulating Feeding Behaviour in Male Wistar Rat Offspring

  2015cites this paper
• Interaction between dopamine and neuropeptide Y in the telencephalon of the Indian major carp, Cirrhinus cirrhosus.

  2015cites this paper
• Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas

  2015cites this paper
• Nicotinic α4 Receptor-Mediated Cholinergic Influences on Food Intake and Activity Patterns in Hypothalamic Circuits

  2015cites this paper
• Mice that are resistant to diet-induced weight loss have greater food anticipatory activity and altered melanocortin-3 receptor (MC3R) and dopamine receptor 2 (D2) gene expression.

  2015cites this paper
• Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

  2015cites this paper
• Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

  2015cites this paper
• Evidence of Liver and Kidney Injuries Attributable To Oral Bromocriptine Methanesulfonate in Mice.

  2014cites this paper
• Neurotrophins and the regulation of energy balance and body weight.

  2014cites this paper
• Impact of Adiposity and Fat Distribution on the Dynamics of Adrenocorticotropin and Cortisol Rhythms

  2014cites this paper
• Increasing vitamin A in post-weaning diets reduces food intake and body weight and modifies gene expression in brains of male rats born to dams fed a high multivitamin diet.

  2014cites this paper
• Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

  2014cites this paper
• Hypothalamic Role in the Insulin Resistance Syndrome

  2013cites this paper
• Socioeconomic Stress by Dopamine Receptor 2 Gene Interactions in the Development of Obesity

  2013cites this paper
• Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat.

  2013cites this paper
• Effect of Cabergoline on Metabolism in Prolactinomas

  2013cites this paper
• Role of prenatal undernutrition in the expression of serotonin, dopamine and leptin receptors in adult mice: Implications of food intake

  2013cites this paper
• Peptidergic signaling brain systems in diabetes mellitus

  2013cites this paper
• The obese brain: neuroendocrine modulations in the reward system

  2013cites this paper
• Crosstalk between metabolic and neuropsychiatric disorders

  2012cites this paper
• The effects of intracerebroventricular injection of ascorbic acid on feeding behavior in male rats

  2012cites this paper
• Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults

  2012cites this paper
• The central nervous system as a promising target to treat diabetes mellitus.

  2012cites this paper
• Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.

  2012cites this paper
• Antipsychotic use and the risk of diabetes in nursing home residents with dementia.

  2011cites this paper
• Hormonal Signaling Systems of the Brain in Diabetes Mellitus

  2011cites this paper
• Animal models of postinfectious obesity: Hypothesis and review

  2011influential citation
• Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study.

  2011cites this paper
• Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.

  2011cites this paper
• The Dopamine Transporter Gene (DAT1) in Obesity and Binge Eating Disorders

  2011cites this paper
• Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus

  2011cites this paper
• Reinforcement and Food Hedonics: A Look at How Energy Deprivation Impacts Food Reward

  2011cites this paper
• Bromocriptine increased operant responding for high fat food but decreased chow intake in both obesity-prone and resistant rats.

  2011cites this paper
• Weighing in the Role of BDNF in the Central Control of Eating Behavior

  2011cites this paper
• Nutrigenomics of Neuradaptogen Amino-Acid-Therapy and Neurometabolic Optimizers: Overcoming carbohydrate bingeing and overeating through neurometabolic mechanisms

  2011cites this paper
• Integrative neurobiology of energy homeostasis-neurocircuits, signals and mediators.

  2010cites this paper
• Alterations of Central Dopamine Receptors Before and After Gastric Bypass Surgery

  2010cites this paper
• Brain-Derived Neurotrophic Factor Regulates Hedonic Feeding by Acting on the Mesolimbic Dopamine System

  2010cites this paper
• A Riddle Wrapped In a Mystery Inside an Enigma: Antipsychotics and Mortality In Persons With Dementia

  2010cites this paper
• Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment

  2010cites this paper
• Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control

  2010cites this paper
• Enhanced Hypothalamic Leptin Signaling in Mice Lacking Dopamine D2 Receptors*

  2010cites this paper
• Energy regulatory signals and food reward.

  2010cites this paper
• Immunological and behavioral consequences of high-fat diet feeding in mice

  2010cites this paper
• Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat

  2010cites this paper
• PET ASSAY OF EXTRASTRIATAL DOPAMINE D 2 /D 3 RECEPTORS

  2009cites this paper
• Hypothalamic orexin, OX1, alphaMSH, NPY and MCRs expression in dopaminergic D2R knockout mice.

  2009cites this paper
• Intranasal Cabergoline: Pharmacokinetic and Pharmacodynamic Studies

  2009cites this paper
• Insulin, leptin, and food reward: update 2008.

  2009cites this paper
• Imaging of Brain Dopamine Pathways: Implications for Understanding Obesity

  2009cites this paper
• Relation of obesity to consummatory and anticipatory food reward.

  2009cites this paper
• Control of energy homeostasis by insulin and leptin: targeting the arcuate nucleus and beyond.

  2009cites this paper
• PET measurement of changes in D2/D3 dopamine receptor binding in a nonhuman primate during chronic deep brain stimulation of the bed nucleus of the stria terminalis.

  2009cites this paper
• Four weeks high fat feeding induces insulin resistance without affecting dopamine release or gene expression patterns in the hypothalamus of C57Bl6 mice.

  2009cites this paper
• High-fat diet decreases tyrosine hydroxylase mRNA expression irrespective of obesity susceptibility in mice.

  2009cites this paper